论文部分内容阅读
过去20多年,何杰金氏淋巴瘤的治疗取得了明显进步,其完全缓解率及长期生存率已达70%左右。但非何杰金氏淋巴瘤的治疗则基本上处于停滞状态,完全缓解率及长期生存率均明显低于何杰金氏病。近10年来,随着非何杰金氏淋巴瘤分型的深化,化疗方法的发展及抗淋巴瘤药物的增加,支持治疗的加强,化疗效果有了显著的提高,现将有关资料综述如下。一、化疗方案淋巴瘤的化学治疗大致经历了3个阶段。第1阶段的化疗方案以CVP(环磷酰胺、长春新碱、强的松)、MOPP(氮芥、长春新碱、甲基苄肼及强的松)、HOP(阿霉素、长春新碱、强的松)等
Over the past 20 years, the treatment of Hodgkin’s lymphoma has made significant progress. The complete remission rate and long-term survival rate have reached about 70%. However, the treatment of non-Hodgkin’s lymphoma is basically in a stagnant state, and the complete remission rate and long-term survival rate are significantly lower than Hodgkin’s disease. In the past 10 years, with the deepening of non-Hodgkin’s lymphoma classification, the development of chemotherapy and the increase of anti-lymphoma drugs, supportive treatment has been strengthened, and the effect of chemotherapy has been significantly improved. The relevant information is now summarized as follows. First, Chemotherapy Lymphoma chemotherapy has gone through three stages. The first stage chemotherapy regimen was CVP (cyclophosphamide, vincristine, prednisone), MOPP (nitrogen mustard, vincristine, procarbazine and prednisone), HOP (adriamycin, vincristine) , prednisone, etc.